Remove Cardiology Remove Containment Remove Development Remove Trials
article thumbnail

Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

The Pharma Data

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Trials 52
article thumbnail

Novartis Entresto receives positive CHMP opinion for pediatric heart failure

The Pharma Data

Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. The positive opinion is based on final data from the 52-week Phase III PANORAMA-HF trial – the largest pediatric heart failure study ever conducted – and extrapolation of adult heart failure data from the Phase III PARADIGM-HF trial to pediatric patients 3,4.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MolecuLight’s CEO Anil Amlani Discusses Next Steps for Their Wound Imaging Devices

XTalks

The Toronto-based company has recently announced positive results from an independent clinical trial which showed that their fluorescence imaging device MolecuLight i :X improved 12-week wound healing of diabetic foot ulcers by 204 percent. Orthopaedics have X-ray, cardiology has echocardiography, cancer has ultrasound, PET, CT and MRI.

Bacteria 111
article thumbnail

Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

The Pharma Data

Caelum”) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.

article thumbnail

Novartis Leqvio®* (inclisiran) analyses show effective and sustained LDL-C reduction.

The Pharma Data

Overall, Leqvio was well-tolerated, with a safety profile similar to placebo and consistent with the overall pooled population from the combined trials 1 – 3. Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC).

RNA 52
article thumbnail

Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

– Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020 – – Expects to exceed the high end of 2020 revenue guidance, given at Q3 2020 results, of $5.9-$5.95 12, 2021– Alexion Pharmaceuticals, Inc. “For

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. The reverse could also be true whereby the development of coronary artery disease may impact heart rate. Heart failure affects about 6.2